Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

835 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Definition of the viral targets of protective HIV-1-specific T cell responses.
Mothe B, Llano A, Ibarrondo J, Daniels M, Miranda C, Zamarreño J, Bach V, Zuniga R, Pérez-Álvarez S, Berger CT, Puertas MC, Martinez-Picado J, Rolland M, Farfan M, Szinger JJ, Hildebrand WH, Yang OO, Sanchez-Merino V, Brumme CJ, Brumme ZL, Heckerman D, Allen TM, Mullins JI, Gómez G, Goulder PJ, Walker BD, Gatell JM, Clotet B, Korber BT, Sanchez J, Brander C. Mothe B, et al. Among authors: gatell jm. J Transl Med. 2011 Dec 7;9:208. doi: 10.1186/1479-5876-9-208. J Transl Med. 2011. PMID: 22152067 Free PMC article.
Effect of maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals.
Kawana-Tachikawa A, Llibre JM, Bravo I, Escrig R, Mothe B, Puig J, Puertas MC, Martinez-Picado J, Blanco J, Manzardo C, Miro JM, Iwamoto A, Pozniak AL, Gatell JM, Clotet B, Brander C; MARAVIBOOST Investigators. Kawana-Tachikawa A, et al. Among authors: gatell jm. PLoS One. 2014 Jan 27;9(1):e87334. doi: 10.1371/journal.pone.0087334. eCollection 2014. PLoS One. 2014. PMID: 24475275 Free PMC article. Clinical Trial.
Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1.
Mothe B, Climent N, Plana M, Rosàs M, Jiménez JL, Muñoz-Fernández MÁ, Puertas MC, Carrillo J, Gonzalez N, León A, Pich J, Arnaiz JA, Gatell JM, Clotet B, Blanco J, Alcamí J, Martinez-Picado J, Alvarez-Fernández C, Sánchez-Palomino S, Guardo AC, Peña J, Benito JM, Rallón N, Gómez CE, Perdiguero B, García-Arriaza J, Esteban M, López Bernaldo de Quirós JC, Brander C, García F; RISVAC-03 Study Group. Mothe B, et al. Among authors: gatell jm. J Antimicrob Chemother. 2015;70(6):1833-42. doi: 10.1093/jac/dkv046. Epub 2015 Feb 26. J Antimicrob Chemother. 2015. PMID: 25724985 Clinical Trial.
Ex vivo production of autologous whole inactivated HIV-1 for clinical use in therapeutic vaccines.
Gil C, Climent N, García F, Hurtado C, Nieto-Márquez S, León A, García MT, Rovira C, Miralles L, Dalmau J, Pumarola T, Almela M, Martinez-Picado J, Lifson JD, Zamora L, Miró JM, Brander C, Clotet B, Gallart T, Gatell JM. Gil C, et al. Among authors: gatell jm. Vaccine. 2011 Aug 5;29(34):5711-24. doi: 10.1016/j.vaccine.2011.05.096. Epub 2011 Jun 14. Vaccine. 2011. PMID: 21679735 Clinical Trial.
Evolution of broadly cross-reactive HIV-1-neutralizing activity: therapy-associated decline, positive association with detectable viremia, and partial restoration of B-cell subpopulations.
Ferreira CB, Merino-Mansilla A, Llano A, Pérez I, Crespo I, Llinas L, Garcia F, Gatell JM, Yuste E, Sanchez-Merino V. Ferreira CB, et al. Among authors: gatell jm. J Virol. 2013 Nov;87(22):12227-36. doi: 10.1128/JVI.02155-13. Epub 2013 Sep 4. J Virol. 2013. PMID: 24006439 Free PMC article.
A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART.
Gómez CE, Perdiguero B, García-Arriaza J, Cepeda V, Sánchez-Sorzano CÓ, Mothe B, Jiménez JL, Muñoz-Fernández MÁ, Gatell JM, López Bernaldo de Quirós JC, Brander C, García F, Esteban M. Gómez CE, et al. Among authors: gatell jm. PLoS One. 2015 Nov 6;10(11):e0141456. doi: 10.1371/journal.pone.0141456. eCollection 2015. PLoS One. 2015. PMID: 26544853 Free PMC article. Clinical Trial.
Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant.
Beltran-Pavez C, Ferreira CB, Merino-Mansilla A, Fabra-Garcia A, Casadella M, Noguera-Julian M, Paredes R, Olvera A, Haro I, Brander C, Garcia F, Gatell JM, Yuste E, Sanchez-Merino V. Beltran-Pavez C, et al. Among authors: gatell jm. PLoS One. 2018 Dec 19;13(12):e0208345. doi: 10.1371/journal.pone.0208345. eCollection 2018. PLoS One. 2018. PMID: 30566493 Free PMC article.
835 results